Role of antibodies and the complement system in the pathology of venous thrombosis in multiple myeloma
Medizinische Klinik und Poliklinik I, Massberg/Schulz
The project will be carried in the working group of Prof. Steffen Massberg, Medical Clinic 1, the cardiology department of the KUM (AG Massberg, Medizinische Klinik und Poliklinik I). The working group is a highly dynamic and collaborative research society consisted of many research groups, focusing on many topics i.e. Immunothrombosis, Atherosclerosis, Cardiovascular Immunology and more… (http://www.klinikum.uni-muenchen.de/Medizinische-Klinik-und-Poliklinik-I/de/Research/Basic-Research/Research-Areas/index.html).
The focus of our research group is Immunothrombosis. We aim to understand the role of the immune system in the development of cardiovascular diseases.
In our international work environment, you can develop your talent and realize ideas within a competent team offering individual and well-structured introduction, training and support (medical doctors, veterinarians, biologists and doctoral students in human medicine). We dispose highly advanced technical facilities (i.e. intravital microscopy, Flow cytometry, Confocal imaging) and a big variety of methods as well (i.e. histology, immunohistochemistry, in vitro and cell culture experiments, Western Blot and ELISA). Our working group respects and celebrates the diversity of our members, and offer a friendly social environment for work and life (Christmas lunch and dinner, hiking days, Oktoberfest, Beer-garden...).
The research project, entitled “Role of antibodies and the complement system in the pathology of venous thrombosis in multiple myeloma” aims to investigate the role of antibodies and the complement system in the pathophysiology of venous thromboembolism in the context of multiple myeloma and to understand the underlying mechanisms. Multiple myeloma patients are exposed to higher risks of venous thromboembolism. At the same time, high bleeding risks are a substantial threat for these patients, thus generating a clinical dilemma of simultaneous high thrombotic and bleeding risks, imposing limitations on the use of anticoagulants to prevent thrombosis.
In this project, we aim to explore the role of antibodies in the pathophysiology of venous thromboembolism in multiple myeloma and to understand the underlying mechanisms.
The results of this project have important implications for venous thromboembolism in multiple myeloma patients: they open the door for new pathways in the prevention of venous thromboembolism, without affecting hemostasis, particularly in this population at high bleeding risk. Based on our findings, we will suggest a new strategy to prevent venous thromboembolism in multiple myeloma bypassing the elevated bleeding risk of anticoagulants.
This project includes a variety of techniques including in vivo experimental surgeries on mice (partial ligation of the inferior vena cava), intravital microscopy performed on mice, confocal imaging, histology, immunohistochemistry, flow cytometry, in vitro and cell culture experiments, Western Blot and ELISA. These methods are
Geschätzte Dauer: 24 Monate
LMU excellent, ERC starting grant.